Systemic T cell adoptive immunotherapy of malignant gliomas

Abstract

These intriguing clinical observations warrant further trials to determine whether this approach can provide therapeutic benefits and improve survival.

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

“…In this context, it has been documented that four out of 12 patients with newly diagnosed glioma who were treated with adoptive transfer of ex vivo-activated T lymphocytes showed partial regression of the tumour (Plautz et al, 2000). In patients with recurrent malignant gliomas, the local administration of in vitro-expanded tumour-reactive T cells resulted in complete or partial tumour regressions (Tsuboi et al, 2003).…”

Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

“…Immunotherapy is theoretically appealing because it offers the potential for a high degree of tumor specificity, whereas sparing normal brain structures. Several different laboratories have shown that effective immune responses within the CNS can be generated through the use of gene-modified tumor cell vaccines (2 -4), the adoptive transfer of immune T cells (5,6), or the use of dendritic cell -based vaccines (7 -11). These results imply that systemic immunity can enter the ''immunologically privileged'' CNS, selectively identify tumor-associated antigens, and destroy brain tumor cells (12).…”

Inmunoterapia en astrocitomas de alto grado: principios y estado actual

“…Consiste en la inmunización previa del paciente con extracto tumoral (asociado a estimuladores inespecíficos de la inmunidad como BCG o GMCSF), cultivo de linfocitos T activados tras la vacuna y posterior reinfusión de dichos linfocitos. Los resultados obtenidos con estas técnicas tampoco han supuesto un aumento de la supervivencia de los pacientes 36,77 . Kruse y colaboradores 50 han estudiado la posibilidad de emplear linfocitos reactivos frente a proteínas del CMH basándose en la teoría de que estas moléculas se expresan con menor intensidad en neuronas y glía que en células tumorales, habiendo obtenido resultados clínicos prometedores.…”